Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update

Area of Science:

• Oncology
• Gastrointestinal Oncology
• Cancer Treatment

Background:

• Stage II colon cancer treatment decisions require careful consideration of recurrence risk.
• Adjuvant therapy plays a crucial role in improving outcomes for resected colon cancer patients.

Purpose of the Study:

• To establish evidence-based recommendations for adjuvant therapy in resected stage II colon cancer.
• To guide clinical practice for oncologists treating this patient population.

Main Methods:

• A systematic review of 21 observational studies and 6 randomized controlled trials was conducted.
• An Expert Panel convened by ASCO synthesized the evidence to formulate clinical practice guidelines.

Main Results:

• Adjuvant chemotherapy (ACT) is generally not recommended for stage II colon cancer without high-risk features.
• Patients with T4 tumors or other high-risk factors (e.g., <12 lymph nodes, poor grade, perforation) may be offered ACT.
• Oxaliplatin addition to ACT is not routine but may be considered in shared decision-making; recommended for mismatch repair deficient/microsatellite instability high-risk patients.

Conclusions:

• Personalized treatment strategies are essential for stage II colon cancer based on risk stratification.
• Shared decision-making is crucial when considering adjuvant chemotherapy, particularly with oxaliplatin-containing regimens.
• Guidelines address chemotherapy duration and adverse event profiles, including peripheral neuropathy.